Proliferative Diabetic Retinopathy Clinical Trial
Official title:
Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept Injection (ELYSIAN)
To assess the safety and efficacy of intravitreal aflibercept injection in the regression of
retinal neovascularization secondary to high-risk PDR.
To characterize baseline/post-induction/maintenance levels of proinflammatory mediators in
patients with high-risk PDR
This study will evaluate two dosing regimens (monthly and PRN following a loading dose) for treatment of PDR with intravitreal aflibercept injection. Additionally, the study will identify biomarker mediators in vitreous fluid present at baseline in patients with PDR and will track over the course of a year their profile changes in response to these two dosing regimens. The treatment regimens will provide information on the biomarker profile with a monthly regimen as well as with a variable regimen. Furthermore, biomarker mediators that may be associated with anti-VEGF responders and non-responders may also be identified. 105 biomarker mediators (cytokines/chemokines) which have been identified as playing a role in PDR in published studies will be profiled in patients with PDR. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01921192 -
Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy
|
Phase 4 | |
| Recruiting |
NCT01044875 -
Trial of Yellow 577 nm Laser Versus Green 532 nm Laser for Proliferative Diabetic Retinopathy
|
N/A | |
| Active, not recruiting |
NCT00993525 -
Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)
|
Phase 1/Phase 2 | |
| Completed |
NCT01307072 -
Compliance to Ophthalmic Follow-up Examinations and Surgical Outcome for Proliferative Diabetic Retinopathy
|
N/A | |
| Completed |
NCT01758757 -
Comparison of Small-gauge Vitrectomy and Conventional Vitrectomy for Proliferative Diabetic Retinopathy
|
N/A | |
| Withdrawn |
NCT00600236 -
HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population
|
Phase 3 | |
| Completed |
NCT05408416 -
Comparison of Surgery Outcome Between Preoperative IVR and Intraoperative IVR in PPV for PDR
|
N/A | |
| Completed |
NCT05414149 -
Efficacy and Safety Comparison of IVR and IVC Before Vitrectomy in Proliferative Diabetic Retinopathy
|
N/A | |
| Not yet recruiting |
NCT04464694 -
Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema
|
Phase 4 | |
| Not yet recruiting |
NCT03633266 -
Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy
|
N/A | |
| Completed |
NCT03490318 -
Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy
|
||
| Completed |
NCT01627977 -
Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy
|
Phase 3 | |
| Completed |
NCT00776763 -
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
|
Phase 2 | |
| Completed |
NCT00682240 -
Morphological and Functional Retinal Changes Following Retinal Photocoagulation
|
Phase 4 | |
| Terminated |
NCT00563043 -
Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment
|
Phase 4 | |
| Terminated |
NCT00563628 -
Changes in Macular Thickness After Patterns Scan Laser
|
Phase 4 | |
| Completed |
NCT00446381 -
Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)
|
N/A | |
| Completed |
NCT02879422 -
Genetic Markers and Proliferative Diabetic Retinopathy
|
N/A | |
| Enrolling by invitation |
NCT02911311 -
Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy
|
N/A | |
| Recruiting |
NCT05514925 -
Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy
|
Phase 4 |